What Happened

TRex Bio and Retension Pharmaceuticals filed SEC registrations for IPOs on Friday, joining ADARx Pharmaceuticals in the 2026 biotech IPO queue. TRex plans to use proceeds for phase 2 trials of TRB-061 in atopic dermatitis and phase 1 work on TRB-071; Retension will fund a phase 2b study of RTN-001 for hypertension and a phase 3 launch. ADARx aims to raise up to $446 million for three clinical-stage siRNA medicines.

Who Is Affected

TRex Bio, a South San Francisco startup with 60 employees and $91 million in cash, is backed by Eli Lilly and Johnson & Johnson. Retension, a 12-person company with $13.5 million, is developing RTN-001. ADARx, backed by AbbVie, is also in the queue. These companies will need clinical trial software, CRO services, and regulatory expertise as they scale.

Market Impact

The IPO window is open, with record listings from Parabilis Medicines and Kailera Therapeutics earlier in 2026. This signals increased spending in clinical operations and data management.

• TRex and Retension will initiate or expand phase 2/3 trials, driving demand for trial management tools.
• ADARx's $446M raise will fund three clinical programs, creating vendor opportunities.
• Lilly's participation in TRex's IPO adds credibility and potential follow-on partnerships.

What to Watch

Watch for TRex's phase 1 topline data in mid-2027 and its phase 2 trial initiation for TRB-061. Retension's phase 2b results for RTN-001 will be critical, and ADARx's pricing will set the tone for biotech IPOs. Monitor hiring and vendor contracts as these companies scale.

Related coverage

• ADARx plans IPO to fund siRNA therapies
• ArsenalBio sheds most of staff in pivot to in vivo CAR-T